Patents Assigned to Pfizer Inc.
  • ESCHERICHIA COLI COMPOSITIONS AND METHODS THEREOF
    Publication number: 20220152181
    Abstract: This invention relates to compositions that include a polypeptide derived from E. coli or a fragment thereof; and modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof, and methods of use thereof.
    Type: Application
    Filed: October 25, 2021
    Publication date: May 19, 2022
    Applicant: Pfizer Inc.
    Inventors: Annaliesa Sybil Anderson, Laurent Oliver Chorro, Robert George Konrad Donald, Jacqueline Marie Lypowy, Rosalind Pan
  • CRYSTALLINE PYRIMIDINYL-3,8-DIAZABICYCLO[3.2.1]OCTANYLMETHANONE COMPOUND AND USE THEREOF
    Publication number: 20220144846
    Abstract: The present invention discloses a novel crystalline form of ((S)-2,2-difluorocyclopropyl)-((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)-pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone free base, pharmaceutical composition containing the same, preparations thereof and uses thereof.
    Type: Application
    Filed: February 12, 2020
    Publication date: May 12, 2022
    Applicant: Pfizer Inc.
    Inventors: Xiaojing YANG, Amanda Patrice Surajhie SAMUEL
  • Nitrile-Containing Antiviral Compounds
    Publication number: 20220142976
    Abstract: The invention relates to compounds of Formula I? wherein R, R1, R2, R3, p, q and q? are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
    Type: Application
    Filed: December 17, 2021
    Publication date: May 12, 2022
    Applicant: Pfizer Inc.
    Inventors: Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Liuqing Wei, Qingyi Yang, Xiaojing Yang
  • TOFACITINIB ORAL SUSTAINED RELEASE DOSAGE FORMS
    Publication number: 20220142927
    Abstract: The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
    Type: Application
    Filed: January 21, 2022
    Publication date: May 12, 2022
    Applicant: PFIZER INC.
    Inventors: Scott Max Herbig, Sriram Krishnaswami, Joseph Kushner, IV, Manisha Lamba, Thomas C. Stock
  • Crystalline 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 4-(4-(1-isopropyl-7-OXO-1,4,6,7-tetrahydrospiro[indazole-5,4?-piperidine]-1?-carbonyl)-6-methoxypryridin-2-YL)benzoic acid
    Patent number: 11325909
    Abstract: The invention provides the tris salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4?-piperidine]-1?-carbonyl)-6-methoxypyridin-2-yl)benzoic acid as a crystalline anhydrous or tri-hydrate; as well as polymorphs, pharmaceutical compositions, dosage forms, and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase (ACC) enzyme(s) in an animal.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: May 10, 2022
    Assignee: Pfizer Inc.
    Inventors: Dilinie Fernando, Shawn Marie LaCasse, Kristin Elizabeth Price Wiglesworth
  • Site-specific integration
    Patent number: 11326185
    Abstract: The present invention relates to stable and high-producing site-specific integration (SSI) host cells, e. g. Chinese hamster ovary (CHO)-derived host cells, methods to produce and to use them.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: May 10, 2022
    Assignees: LONZA BIOLOGICS PLC, PFIZER INC.
    Inventors: James Rance, Robert Young, Michael J. Agostino, Mark Moffat, Lin Zhang, Baohong Zhang
  • Methods for purifying bacterial polysaccharides
    Publication number: 20220136020
    Abstract: The present invention relates to methods for purifying bacterial polysaccharides, in particular for removing impurities from cellular lysates of bacteria producing polysaccharides.
    Type: Application
    Filed: February 20, 2020
    Publication date: May 5, 2022
    Applicant: Pfizer Inc.
    Inventors: Ling Chu, Scott Andrew Cook, Nishith Merchant, Justin Keith Moran
  • MANUFACTURING PROCESS AND INTERMEDIATES FOR A PYRROLO[2,3-D]PYRIMIDINE COMPOUND AND USE THEREOF
    Publication number: 20220127274
    Abstract: The present invention relates to a manufacturing process and intermediates for preparing a crystalline or non-crystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide. The present invention also relates to salt forms and pharmaceutical compositions comprising the crystalline form, and to methods for use of the compound prepared from a crystalline form in the treatment of various diseases.
    Type: Application
    Filed: January 10, 2022
    Publication date: April 28, 2022
    Applicant: Pfizer Inc.
    Inventors: Kapildev Kashmirilal Arora, Jacob Cole DeForest, Andrew Kevern Hills, Brian Patrick Jones, Kris Nicole Jones, Chad Arthur Lewis, Anil Mahadeo Rane
  • COMBINATION OF A CDK INHIBITOR AND A PIM INHIBITOR
    Publication number: 20220125777
    Abstract: This invention relates to combination therapies comprising a cyclin dependent kinase (CDK) inhibitor, in particular a CDK4/6 inhibitor, and a proviral integration site for Moloney murine leukemia virus (PIM) inhibitor, and associated pharmaceutical compositions, methods of treatment, and uses.
    Type: Application
    Filed: January 31, 2020
    Publication date: April 28, 2022
    Applicant: Pfizer Inc.
    Inventors: Zhou Zhu, Yuan Liu
  • CRYSTALLINE FORM OF A CDK INHIBITOR
    Publication number: 20220127262
    Abstract: The invention relates to a crystalline form of 6-(difluoromethyl)-8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-{[1-(methylsulfonyl) piperidin-4-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one (PF-06873600) free base (Form 1).
    Type: Application
    Filed: January 13, 2020
    Publication date: April 28, 2022
    Applicant: Pfizer Inc.
    Inventors: Douglas Carl Behenna, Martha Alicia Ornelas
  • Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors
    Patent number: 11312713
    Abstract: The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R1, R2 and R3 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: April 26, 2022
    Assignee: Pfizer Inc.
    Inventors: Michael Aaron Brodney, Thomas Allen Chappie, Jinshan Michael Chen, Jotham Wadsworth Coe, Karen Jean Coffman, Paul Galatsis, Michelle Renee Garnsey, Christopher John Helal, Jaclyn Louise Henderson, Bethany Lyn Kormos, Ravi G. Kurumbail, Luis Angel Martinez-Alsina, Martin Youngjin Pettersson, Matthew Richard Reese, Colin Richard Rose, Antonia Friederike Stepan, Patrick Robert Verhoest, Travis T. Wager, Joseph Scott Warmus, Yuan Zhang
  • Chimeric antigen receptors targeting B-cell maturation antigen
    Patent number: 11312782
    Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: April 26, 2022
    Assignee: Pfizer Inc.
    Inventors: Tracy Chia-Chien Kuo, Bijan Andre Boldajipour, Javier Fernando Chaparro Riggers, Philippe Duchateau, Roman Ariel Galetto, Alexandre Juillerat, Thomas Charles Pertel, Arvind Rajpal, Barbra Johnson Sasu, Cesar Adolfo Sommer, Julien Valton, Thomas John Van Blarcom
  • CD1a ANTIBODIES AND USES THEREOF
    Publication number: 20220112291
    Abstract: Antibodies, and antigen-binding fragments thereof, that specifically bind to Cluster of Differentiation 1a (CD1a) are provided. Embodiments include uses, and associated methods of using the antibodies, and antigen-binding fragments thereof.
    Type: Application
    Filed: October 7, 2021
    Publication date: April 14, 2022
    Applicants: Pfizer Inc., Children's Medical Center Corporation
    Inventors: Florian WINAU, Oleg V. KOVALENKO, Chew Shun CHANG, Di WU, Nicholas Andrew MARZE, Shian-Huey CHIANG
  • Crystalline form of lorlatinib free base hydrate
    Patent number: 11299500
    Abstract: This invention relates to a crystalline form of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclo-tetradecine-3-carbonitrile (lorlatinib) free base hydrate (Form 24). This invention also relates to pharmaceutical compositions comprising Form 24, and to methods of using Form 24 and such compositions in the treatment of abnormal cell growth, such as cancer, in a mammal.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: April 12, 2022
    Assignee: Pfizer Inc.
    Inventors: Paul Bowles, Peter Robert Rose
  • CYCLIN DEPENDENT KINASE INHIBITORS
    Publication number: 20220089580
    Abstract: This invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, in which R-groups R1 to R23, A, Q, U, V, W, X, Y, Z, n, p and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.
    Type: Application
    Filed: December 7, 2021
    Publication date: March 24, 2022
    Applicant: Pfizer Inc.
    Inventors: Ping Chen, Sujin Cho-Schultz, Judith Gail Deal, Gary Michael Gallego, Mehran Jalaie, Robert Steven Kania, Sajiv Krishnan Nair, Sacha Ninkovic, Suvi Tuula Marjukka Orr, Cynthia Louise Palmer
  • Antibodies specific for epidermal growth factor receptor variant III and their uses
    Patent number: 11279764
    Abstract: The present invention provides antibodies that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further provides bispecific antibodies that bind to EGFRvIII and another antigen (e.g., CD3) as well as antibody conjugates (e.g., antibody-drug-conjugates). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific) and antibody conjugates. The invention further relates to therapeutic methods for use of these antibodies and antibody conjugates for the treatment of EGFRvIII-mediated pathologies, including cancer such as glioblastoma.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: March 22, 2022
    Assignee: Pfizer Inc.
    Inventors: Oi Kwan Wong, Joyce Ching Chou, Barbra Johnson Sasu
  • Dosing regimen of avelumab for the treatment of cancer
    Patent number: 11274154
    Abstract: The present invention relates to dosing regimen of avelumab for the treatment of cancer. In particular, the invention relates to improved dosing regimen of avelumab for the treatment of cancer.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: March 15, 2022
    Assignees: PFIZER INC., MERCK PATENT GMBH
    Inventors: Glen Ian Andrews, Carlo Leonel Bello, Satjit Singh Brar, Shaonan Wang, Pascal Girard
  • Cells with reduced inhibitor production and methods of use thereof
    Publication number: 20220073942
    Abstract: The invention relates to a method of cell culture where the cells are modified to reduce the level of synthesis of growth and/or productivity inhibitors by the cell. The invention also relates to a method of cell culture for improving cell growth and productivity, in particular in culture of mammalian cells at high cell density. The invention further relates to a method of producing cells with improved cell growth and/or productivity in cell culture and to cells obtained or obtainable by such methods.
    Type: Application
    Filed: December 3, 2019
    Publication date: March 10, 2022
    Applicant: PFIZER INC.
    Inventors: Emily Ann DEUTSCHMAN, Jeffrey Joseph MITCHELL, Bhanu Chandra MULUKUTLA, John Joseph SCARCELLI
  • Pharmaceutical Compositions and Methods Comprising A Combination of a Benzoxazole Transthyretin Stabilizer and an Additional Therapeutic Agent
    Publication number: 20220071965
    Abstract: The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a benzoxazole derivative transthyretin stabilizer or a pharmaceutically acceptable salt or prodrug thereof and an additional therapeutic agent for the treatment of transthyretin amyloidosis. Particularly, the present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or a pharmaceutically acceptable salt or prodrug thereof and one or more additional therapeutic agent for the treatment of transthyretin amyloidosis.
    Type: Application
    Filed: December 17, 2019
    Publication date: March 10, 2022
    Applicant: Pfizer Inc.
    Inventors: Christine Ellen Bulawa, James Allan Fleming
  • Chimeric antigen receptors targeting epidermal growth factor receptor variant III
    Patent number: 11267892
    Abstract: The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making thereof, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for using these CARs and engineered immune cells for the treatment of EGFRvIII-mediated pathologies, including cancers such as glioblastoma.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: March 8, 2022
    Assignee: Pfizer Inc.
    Inventors: Oi Kwan Wong, Joyce Ching Chou, Mathilde Brunnhilde Dusseaux, Julianne Smith, Barbra Johnson Sasu